The IDEAL-PCI Extended Registry

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Extended Registry

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02974777

Acronym

IDEAL-PCI ext

Enrollment

Registered

2016-11-28

Start date

Unknown

Completion date

2017-01-31

Last updated

2018-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Arterioscleroses, Platelet Dysfunction Due to Drugs

Brief summary

The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating on-treatment platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer). IDEAL-PCI Extended is the continuation of the IDEAL-PCI registry with additional focus on bleeding events and net clinical benefit

Detailed description

Determination of platelet reactivity in patients with percutaneous coronary Intervention as described in the IDEAL-PCI registry. In the IDEAL-PCI Extended Registry an additional deescalation arm with reduction of the standard dual antiplatelet therapy (DAPT) dosis in case of low platelet reactivity to P2Y12 Inhibition or Aspirin with or without bleeding is implemented.

Interventions

DRUGDAPT reduction

Reduction of standard dose DAPT due to low platelet reactivity

DRUGDAPT on-target

Standard DAPT within the therapeutic window of platelet reactivity

DRUGDAPT intensification

Intensification of standard dose DAPT due to high platelet reactivity

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* all consecutive PCI patients

Exclusion criteria

* pregnancy

Design outcomes

Primary

Measure	Time frame	Description
stent thrombosis	1 year	stent thrombosis by any Academic Research Consortium (ARC) definition
bleeding	1 year	bleeding type 1-3 and 5 by Bleeding Academic Research Consortium (BARC) definition

Secondary

Measure	Time frame	Description
Major adverse cardiac and cerebrovascular Events (MACCE)	1 year	death, cardiovascular death, myocardial infarction, stroke, ischemia driven revascularization

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026